Primary Job Title CSO Primary Organization 
Orca Pharmaceuticals
Location Oxford, Oxfordshire, United Kingdom Regions Europe, Middle East, and Africa (EMEA) Gender Male
Website www.atopixtherapeutics.com/ LinkedIn View on LinkedIn
Dr Pettipher has over 25 years’ experience in anti-inflammatory drug discovery having previously worked at Pfizer (1990−1997) and Wellcome Laboratories (1984−1990). At Oxagen Ltd, he was involved in the initiation and management of its anti-inflammatory CRTH2 antagonist program which has yielded a clinical candidate, currently in Phase 2b trials.
He has extensive experience in drug discovery and in non-clinical and clinical development, most recently in asthma and related allergic conditions.
He holds a degree in Pharmacology from the University of Bath, a PhD in Pharmacology from the University of London and an MBA from Imperial College, London.
Dr Roy Pettipher has responsibility for all aspects of inflammation biology and pharmacology for Atopix. He has been Director of Research at Oxagen Ltd for the past 14 years where he initiated the CRTH2 antagonist program. Roy gained 13 years experience in anti-inflammatory drug discovery during his time at Pfizer in the US and, previous to that, at Wellcome in the UK.
Less
